Plans to create one of the world’s biggest pharmaceutical companies have fallen foul of the US government’s tough new stance on corporate tax inversions, after US pharma giant AbbVie abandoned its proposed $54bn (£34bn) takeover of UK drugs manufacturer Shire on the grounds the deal will no longer deliver the anticipated tax benefits